Farmacogenética del metotrexato en artritis reumatoide. Revisión sistemática

Restrepo, Luisa F.; Giraldo, Rodrigo; Londoño, John; Pinzón, Carlos; Cortes, Ani; Ballesteros, G.; Santos, Ana Maria Ribeiro dos

doi:10.1016/j.rcreu.2016.02.002

Cited by 5 publications

(3 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in silico data suggest that these SNPs may have a direct role in regulating the expression of their target genes. In this regard, SNPs in the ATIC gene, including rs3821353, can affect the bifunctional protein that catalyzes the last two steps of the de novo purine biosynthetic pathway [ 30 ]. Additionally, it can cause alterations in AMP-activated protein kinase (AMPK) signaling pathways [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

“…In this regard, SNPs in the ATIC gene, including rs3821353, can affect the bifunctional protein that catalyzes the last two steps of the de novo purine biosynthetic pathway [ 30 ]. Additionally, it can cause alterations in AMP-activated protein kinase (AMPK) signaling pathways [ 30 ]. For the DHFR gene, SNPs within this gene, including rs10072026, can affect the metabolism of water-soluble vitamins and cofactors, fluoropyrimidine activity, cell cycle, and mitotic G1 phase and G1/S transition pathways [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacogenomics of Methotrexate Pathway in Rheumatoid Arthritis Patients: Approach toward Personalized Medicine

et al. 2022

View full text Add to dashboard Cite

Background: Methotrexate (MTX) is one of the most common medications used for rheumatoid arthritis (RA) treatment. Single-nucleotide polymorphisms (SNPs) could potentially predict variability in therapeutic outcomes. Aim: This study aims to assess the impact of SNPs in genes encoding for the MTX pathway for predicting clinical and therapeutic responses to MTX in a cohort of Egyptian patients with RA. Subjects and Methods: Data from 107 Egyptian RA patients (aged 44.4 ± 11.4 years) treated with MTX monotherapy, for a duration of 3.7 ± 3.3 years, were collected. Genotypes of 10 SNPs from four different genes were analyzed using the allelic discrimination PCR technique. Results: The ATIC rs3821353 G/T (p = 0.034) and the C/T and C/C of SLC19A1 rs7279445 (p = 0.0018) were associated with a non-response to MTX, while DHFR rs10072026 C/T and C/C were associated with a good response (p < 0.001). Carriers of the ATIC rs382135 3 G (p = 0.001) and ATIC rs4673990 G (p < 0.001) alleles were more likely to develop RA, while the SLC19A1 rs11702425 T (p < 0.001) and GGH rs12681874 T (p = 0.003) allele carriers were more likely to be protected against RA. Carriers of the ATIC rs4673990 A/G genotype (p < 0.001) were at risk of developing RA, while carriers of the following genotypes were mostly protected against RA: ATIC rs3821353 T/T (p < 0.001), ATIC rs3821353 G/G (p = 0.004), SLC19A1 rs11702425 T/T (p = 0.001), SLC19A1 rs11702425 C/T (p = 0.003), GGH rs12681874 C/T (p = 0.004) and GGH rs12681874 T/T (0.002). Conclusion: The genotyping of genes involved in the MTX pathway may be helpful to predict which RA patients will/will not benefit from MTX, and thus, may help to apply a personalized medicine approach in RA.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Pharmacogenomics of Methotrexate Pathway in Rheumatoid Arthritis Patients: Approach toward Personalized Medicine

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Este mediador activa receptores extracelulares A2a, A2b y A3 en los monocitos y los macrófagos, inhibe la producción de factor de necrosis tumoral alfa (TNF), IL-6 e IL-8, promueve la transcripción de ARNm para el receptor antagonista de IL-1 y aumenta la secreción IL-10, potente antiinflamatorio. La activación de los receptores de adenosina sobre las células endoteliales humanas inhibe la producción de IL-6 e IL-8 y disminuye la expresión de E-selectina en la superficie celular 4 .…”

Section: Introductionunclassified

Adverse effects of methotrexate in a rheumatology outpatient clinic

Álvarez-Femayor

Aray-Álvarez

Fuentes-Silva

2022

Rev. parag. reumatol

View full text Add to dashboard Cite

Introducción: El metotrexate (MTX) es un fármaco ampliamente utilizado en el tratamiento de diversas enfermedades reumáticas como artritis reumatoide y artritis psoriásica, siendo un medicamento bien tolerado, económico y con eficacia comprobada en el control de los síntomas articulares y extraarticulares. metodología: Se realizó un estudio descriptivo, retrospectivo, transversal; se revisaron 1.441 historias médicas de una Consulta Externa Privada de Reumatología en el Centro Clínico Universitario de Oriente en Ciudad Bolívar, Venezuela en el periodo diciembre 2011 a diciembre 2019; de esas historias se seleccionaron 202 historias de pacientes que recibieron MTX, excluyéndose 52 historias porque no cumplieron consultas sucesivas, quedando para el análisis 150 historias. Resultados: la muestra estuvo representada por 150 pacientes, cuya edad promedio fue de 50,2±14,3 años, el sexo predominante fue el femenino con 83,3% (n=125). La principal indicación del metotrexate fue para el tratamiento de artritis reumatoide con 56,0% (n=84). Se presentaron efectos adversos en 16,7% de los casos, siendo la intolerancia gástrica el más frecuente con 36,0% (9 pacientes). No se encontró relación con la dosis del metotrexate y la presentación de efectos adversos. Conclusión: Se evidenció una baja tasa de efectos adversos al MTX en pacientes con enfermedades reumáticas, no relacionado a la dosis y en menos del 10% de los casos fue necesario realizar cambio de tratamiento.

show abstract